<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549770</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2201</org_study_id>
    <nct_id>NCT00549770</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696A in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a dose-ranging efficiacy study in patients with essential hypertension to
      assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and
      placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of the study at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Mean Ambulatory DBP (maDBP) and maSBP</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime maDBP and maSBP</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the avergae of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nighttime maDBP and maSBP</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Successful Response in msDBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Successful Response in msSBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Successful Control in msDBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful control in msDBP is defined as msDBP &lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Successful Control in msSBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful control in msSBP is defined as &lt;140 mmHg.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1334</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 320 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AHU377 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_label>Valsartan 160 mg</arm_group_label>
    <arm_group_label>Valsartan 320 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AHU377</intervention_name>
    <arm_group_label>AHU377 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_label>Valsartan 160 mg</arm_group_label>
    <arm_group_label>Valsartan 320 mg</arm_group_label>
    <arm_group_label>AHU377 200 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females from 18 up to and including 75 years

          -  Patients with mild-to-moderate uncomplicated essential hypertension, untreated or
             currently taking antihypertensive therapy (monotherapy or combination therapy of 2
             drugs; therapy with a fixed dose combination of two active substances represents 2
             drugs)

          -  Untreated patients must have had an office msDBP≥ 95 mmHg at the randomization visit
             (Visit 3) and the 2 preceding visits (Visits 1 and 2).

          -  Treated patients must have had an office msDBP≥ 90 mmHG after washout (Visit 2), and a
             msDBP&gt; 95 mmHg at baseline (Visit 3);

        Exclusion Criteria:

          -  Severe hypertension (msSBP ≥180 mmHg and/or msDBP ≥110 mmHg)

          -  History of angioedema, drug-related or otherwise, as reported by the patient

          -  Type 1 or Type 2 diabetes mellitus (according to the ADA criteria)

          -  History or evidence of a secondary form of hypertension, such as renal parenchymal
             hypertension, renovascular hypertension, coarctation of the aorta, primary
             hyperaldosteronism, Cushing's disease, drug-induced hypertension, unilateral or
             bilateral renal artery stenosis, pheochromocytoma, polycystic kidney disease, etc.

          -  History of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic
             heart disease, surgical or percutaneous arterial intervention of any kind (coronary,
             carotid or peripheral intervention), stroke, TIA (transient ischemic attack), carotid
             artery stenosis, aortic aneurysm or peripheral arterial disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orangevale</city>
        <state>California</state>
        <zip>95662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430-2168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132-4904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1408INH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1416DRJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425AST</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CXH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>M4T 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Longueil</city>
        <state>Quebec</state>
        <zip>J4N 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7H 5M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg SV</city>
        <zip>9200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Espergærde</city>
        <zip>3060</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greve</city>
        <zip>2670</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roslev</city>
        <zip>7870</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vaerloese</city>
        <zip>DK-3500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00350</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00810</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kerava</city>
        <zip>04200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bourges</city>
        <zip>18000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Chapelle sur Erdre</city>
        <zip>44240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Pradet</city>
        <zip>83220</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murs Erigné</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Avertin</city>
        <zip>37550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vihiers</city>
        <zip>49310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balve</city>
        <zip>58802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beckingen</city>
        <zip>66701</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Einbeck</city>
        <zip>37574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Giengen</city>
        <zip>89537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haigerloch</city>
        <zip>72401</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krefeld</city>
        <zip>47798</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mahlberg</city>
        <zip>77972</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messkirch</city>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wallerfing</city>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caserta</city>
        <state>CE</state>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozzilli</city>
        <state>IS</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vimercate</city>
        <state>MI</state>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Casorate Primo</city>
        <state>PV</state>
        <zip>27022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stradella</city>
        <state>PV</state>
        <zip>27049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mercato San Severino</city>
        <state>SA</state>
        <zip>84085</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Daniele Del Friuli</city>
        <state>UD</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vibo Valentia</city>
        <state>VV</state>
        <zip>89900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavplis</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuldiga</city>
        <zip>LV-3300</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogre</city>
        <zip>5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alytus</city>
        <zip>LT-62381</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>3007</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49387</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Bosch</city>
        <zip>5216 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deurne</city>
        <zip>5751 XJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ermelo</city>
        <zip>3851 EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoogwoud</city>
        <zip>1718 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Losser</city>
        <zip>7581 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oude Pekela</city>
        <zip>9665 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poortvliet</city>
        <zip>4693 BT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wamel</city>
        <zip>6659 BX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S.-Petersburg</city>
        <zip>191187</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S.-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <state>Slovak Republic</state>
        <zip>974 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <state>Slovak Republic</state>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <state>Slovak Republic</state>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dunajska Streda</city>
        <zip>929 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Cataluña</state>
        <zip>08914</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarrega</city>
        <state>Cataluña</state>
        <zip>25300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vic</city>
        <state>Cataluña</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Benidorm</city>
        <state>Comunidad Valenciana</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quart de Poblet</city>
        <state>Comunidad Valenciana</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>460009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Begonte</city>
        <state>Galicia</state>
        <zip>27373</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llbregat</city>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrel</city>
        <zip>03610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riudecols</city>
        <zip>43390</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arvidsjaur</city>
        <zip>933 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boden</city>
        <zip>SE 961 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlstad</city>
        <zip>652 25</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kil</city>
        <zip>665 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 54</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skellefteå</city>
        <zip>SE 931 32</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <state>Taiwan ROC</state>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan 704</city>
        <state>Taiwan ROC</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <results_first_submitted>August 10, 2012</results_first_submitted>
  <results_first_submitted_qc>July 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2015</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, valsartan, LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study comprised 3 periods: a 4-week washout and placebo run-in period (pre-randomization), an 8-week randomized, double-blind monotherapy period, and 1-week randomized, placebo-controlled withdrawal period. In the randomized withdrawal, participants were either randomized to placebo or continued their original assigned treatment.</recruitment_details>
      <pre_assignment_details>After successful completion of the pre-randomization period, participants were randomized 1:1:1:1:1:1:1:1 ratio to one of 8 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 100 mg</title>
          <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P3">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P4">
          <title>Valsartan 80 mg</title>
          <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P5">
          <title>Valsartan 160 mg</title>
          <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P6">
          <title>Valsartan 320 mg</title>
          <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P7">
          <title>AHU377 200 mg</title>
          <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="172"/>
                <participants group_id="P4" count="163"/>
                <participants group_id="P5" count="166"/>
                <participants group_id="P6" count="164"/>
                <participants group_id="P7" count="165"/>
                <participants group_id="P8" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat Population</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="170"/>
                <participants group_id="P4" count="163"/>
                <participants group_id="P5" count="163"/>
                <participants group_id="P6" count="163"/>
                <participants group_id="P7" count="164"/>
                <participants group_id="P8" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ambulatory Blood Pressure Monitoring</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="162"/>
                <participants group_id="P4" count="147"/>
                <participants group_id="P5" count="149"/>
                <participants group_id="P6" count="151"/>
                <participants group_id="P7" count="151"/>
                <participants group_id="P8" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure results</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 100 mg</title>
          <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B3">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B4">
          <title>Valsartan 80 mg</title>
          <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B5">
          <title>Valsartan 160 mg</title>
          <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B6">
          <title>Valsartan 320 mg</title>
          <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B7">
          <title>AHU377 200 mg</title>
          <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="172"/>
            <count group_id="B4" value="163"/>
            <count group_id="B5" value="166"/>
            <count group_id="B6" value="164"/>
            <count group_id="B7" value="165"/>
            <count group_id="B8" value="173"/>
            <count group_id="B9" value="1328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="10.4"/>
                    <measurement group_id="B2" value="54" spread="9.7"/>
                    <measurement group_id="B3" value="52" spread="10.9"/>
                    <measurement group_id="B4" value="53" spread="9.6"/>
                    <measurement group_id="B5" value="53" spread="9.7"/>
                    <measurement group_id="B6" value="53" spread="10.1"/>
                    <measurement group_id="B7" value="53" spread="10.7"/>
                    <measurement group_id="B8" value="54" spread="10.6"/>
                    <measurement group_id="B9" value="53" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="75"/>
                    <measurement group_id="B8" value="79"/>
                    <measurement group_id="B9" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="98"/>
                    <measurement group_id="B6" value="99"/>
                    <measurement group_id="B7" value="90"/>
                    <measurement group_id="B8" value="94"/>
                    <measurement group_id="B9" value="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, week 8</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.97" spread="0.73"/>
                    <measurement group_id="O2" value="-12.92" spread="0.70"/>
                    <measurement group_id="O3" value="-13.63" spread="0.70"/>
                    <measurement group_id="O4" value="-9.14" spread="0.72"/>
                    <measurement group_id="O5" value="-9.95" spread="0.71"/>
                    <measurement group_id="O6" value="-10.93" spread="0.71"/>
                    <measurement group_id="O7" value="-9.76" spread="0.71"/>
                    <measurement group_id="O8" value="-6.78" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <description>Sitting BP measurements were performed at screening through the end of the study at every study visit.</description>
        <time_frame>baseline, week 8</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <description>Sitting BP measurements were performed at screening through the end of the study at every study visit.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.75" spread="1.15"/>
                    <measurement group_id="O2" value="-18.70" spread="1.10"/>
                    <measurement group_id="O3" value="-20.17" spread="1.10"/>
                    <measurement group_id="O4" value="-12.44" spread="1.12"/>
                    <measurement group_id="O5" value="-13.42" spread="1.12"/>
                    <measurement group_id="O6" value="-14.16" spread="1.12"/>
                    <measurement group_id="O7" value="-11.93" spread="1.11"/>
                    <measurement group_id="O8" value="-7.72" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-hour Mean Ambulatory DBP (maDBP) and maSBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Ambulatory Blood Pressure Monitoring (ABPM) Subset: The ABPM subest included all ITT participants who had both baseline and week 8 ABPM values.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Mean Ambulatory DBP (maDBP) and maSBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8.</description>
          <population>Ambulatory Blood Pressure Monitoring (ABPM) Subset: The ABPM subest included all ITT participants who had both baseline and week 8 ABPM values.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="0.72"/>
                    <measurement group_id="O2" value="-6.78" spread="0.64"/>
                    <measurement group_id="O3" value="-8.32" spread="0.71"/>
                    <measurement group_id="O4" value="-4.56" spread="0.67"/>
                    <measurement group_id="O5" value="-6.25" spread="0.70"/>
                    <measurement group_id="O6" value="-7.13" spread="0.67"/>
                    <measurement group_id="O7" value="-3.67" spread="0.70"/>
                    <measurement group_id="O8" value="-1.33" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="1.04"/>
                    <measurement group_id="O2" value="-11.50" spread="0.93"/>
                    <measurement group_id="O3" value="-14.56" spread="1.03"/>
                    <measurement group_id="O4" value="-7.29" spread="0.96"/>
                    <measurement group_id="O5" value="-8.27" spread="1.00"/>
                    <measurement group_id="O6" value="-9.42" spread="0.97"/>
                    <measurement group_id="O7" value="-5.18" spread="1.02"/>
                    <measurement group_id="O8" value="-2.90" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime maDBP and maSBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the avergae of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Ambulatory Blood Pressure Monitoring (ABPM) Subset: The ABPM subest included all ITT participants who had both baseline and week 8 ABPM values.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime maDBP and maSBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the avergae of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm.</description>
          <population>Ambulatory Blood Pressure Monitoring (ABPM) Subset: The ABPM subest included all ITT participants who had both baseline and week 8 ABPM values.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" spread="1.23"/>
                    <measurement group_id="O2" value="-6.91" spread="1.12"/>
                    <measurement group_id="O3" value="-7.80" spread="1.19"/>
                    <measurement group_id="O4" value="-4.78" spread="1.17"/>
                    <measurement group_id="O5" value="-7.40" spread="1.23"/>
                    <measurement group_id="O6" value="-7.47" spread="1.17"/>
                    <measurement group_id="O7" value="-3.18" spread="1.22"/>
                    <measurement group_id="O8" value="-1.53" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.96" spread="1.73"/>
                    <measurement group_id="O2" value="-11.76" spread="1.58"/>
                    <measurement group_id="O3" value="-14.20" spread="1.67"/>
                    <measurement group_id="O4" value="-7.59" spread="1.65"/>
                    <measurement group_id="O5" value="-9.54" spread="1.73"/>
                    <measurement group_id="O6" value="-9.90" spread="1.66"/>
                    <measurement group_id="O7" value="-4.49" spread="1.72"/>
                    <measurement group_id="O8" value="-3.40" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nighttime maDBP and maSBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Participants from the ABPM subset, who had both baseline nighttime and week 8 nighttime values, were included in the analysis only.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime maDBP and maSBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am.</description>
          <population>Participants from the ABPM subset, who had both baseline nighttime and week 8 nighttime values, were included in the analysis only.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="1.25"/>
                    <measurement group_id="O2" value="-7.73" spread="1.13"/>
                    <measurement group_id="O3" value="-6.93" spread="1.23"/>
                    <measurement group_id="O4" value="-4.04" spread="1.17"/>
                    <measurement group_id="O5" value="-4.18" spread="1.24"/>
                    <measurement group_id="O6" value="-6.17" spread="1.18"/>
                    <measurement group_id="O7" value="-3.31" spread="1.24"/>
                    <measurement group_id="O8" value="-1.01" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="1.77"/>
                    <measurement group_id="O2" value="-11.85" spread="1.60"/>
                    <measurement group_id="O3" value="-12.04" spread="1.73"/>
                    <measurement group_id="O4" value="-6.43" spread="1.66"/>
                    <measurement group_id="O5" value="-5.82" spread="1.74"/>
                    <measurement group_id="O6" value="-7.51" spread="1.67"/>
                    <measurement group_id="O7" value="-3.99" spread="1.75"/>
                    <measurement group_id="O8" value="-2.09" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Successful Response in msDBP</title>
        <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Successful Response in msDBP</title>
          <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.90"/>
                    <measurement group_id="O2" value="69.64"/>
                    <measurement group_id="O3" value="74.12"/>
                    <measurement group_id="O4" value="51.53"/>
                    <measurement group_id="O5" value="55.83"/>
                    <measurement group_id="O6" value="63.19"/>
                    <measurement group_id="O7" value="54.27"/>
                    <measurement group_id="O8" value="39.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Successful Response in msSBP</title>
        <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Successful Response in msSBP</title>
          <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.84"/>
                    <measurement group_id="O2" value="63.69"/>
                    <measurement group_id="O3" value="72.35"/>
                    <measurement group_id="O4" value="51.53"/>
                    <measurement group_id="O5" value="51.53"/>
                    <measurement group_id="O6" value="57.06"/>
                    <measurement group_id="O7" value="46.34"/>
                    <measurement group_id="O8" value="37.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Successful Control in msDBP</title>
        <description>Successful control in msDBP is defined as msDBP &lt;90 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Successful Control in msDBP</title>
          <description>Successful control in msDBP is defined as msDBP &lt;90 mmHg.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.40"/>
                    <measurement group_id="O2" value="60.12"/>
                    <measurement group_id="O3" value="65.88"/>
                    <measurement group_id="O4" value="45.40"/>
                    <measurement group_id="O5" value="47.85"/>
                    <measurement group_id="O6" value="56.44"/>
                    <measurement group_id="O7" value="46.95"/>
                    <measurement group_id="O8" value="38.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Successful Control in msSBP</title>
        <description>Successful control in msSBP is defined as &lt;140 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 160 mg</title>
            <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 320 mg</title>
            <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O7">
            <title>AHU377 200 mg</title>
            <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Successful Control in msSBP</title>
          <description>Successful control in msSBP is defined as &lt;140 mmHg.</description>
          <population>Intent-to-treat (ITT): The ITT included all randomized participants who had a baseline and at least one post-baseline efficacy measuremet during the 8-week core treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="164"/>
                <count group_id="O8" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.40"/>
                    <measurement group_id="O2" value="56.55"/>
                    <measurement group_id="O3" value="62.94"/>
                    <measurement group_id="O4" value="45.40"/>
                    <measurement group_id="O5" value="42.33"/>
                    <measurement group_id="O6" value="53.37"/>
                    <measurement group_id="O7" value="37.20"/>
                    <measurement group_id="O8" value="31.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 100 mg</title>
          <description>Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E3">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E4">
          <title>Valsartan 80 mg</title>
          <description>Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E5">
          <title>Valsartan 160 mg</title>
          <description>Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E6">
          <title>Valsartan 320 mg</title>
          <description>Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E7">
          <title>AHU377 200 mg</title>
          <description>Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

